, a reduction in cell number and resorption was observed. Co 2+ and Cr 6+ within the clinical range reduced cell number and resorption in mature osteoclasts. Our data suggests that metal ions at equivalent concentrations to those found in MOMHR affect bone cell health and may contribute to the observed bone-related complications of these prostheses.
INTRODUCTION
In recent years total hip replacement using large diameter metal-on-metal bearings (MOMHR), either as a hip resurfacing procedure or using a stemmed femoral prosthesis, has become a common alternative to conventional total hip arthroplasty (THA) for the treatment of young and active arthritis patients because of advantages of lower volumetric wear and dislocation risk [1] . However, the clinical outcomes of hip replacement using these prostheses have been mixed. Data from the National Joint Register for England and Wales (2008) demonstrated a 3-year revision rate for hip resurfacing of 4.4% (95%CI 4.0 to 5.0) compared with 1.3% (1.2 to 1.4) for cemented THA (www.njrcentre.org.uk). The Australian arthroplasty register (1997 to 2005) also reported a higher 3-year revision rate for hip resurfacing versus THA (3.1% (2.7 to 3.6) versus 2.1% (1.9 to 2.5%) www.dmac.adelaide.edu.au/aoanjrr). The most common adverse events necessitating revision surgery after MOMHR include early periprosthetic fracture, osteolysis, failure of prosthesis osseo-integration resulting in aseptic loosening, unexplained pain, and inflammatory masses [2] [3] [4] [5] [6] [7] .
Circulating physiological levels of cobalt and chromium are normally <0.25μg/L (0.005μM). Elevated levels of cobalt and chromium occur in both the hip synovial fluid and in peripheral blood after MOMHR. Whole blood concentrations of cobalt and chromium after MOMHR of up to 4.6μM and 2.3μM, respectively [8] , and local hip synovial fluid levels of up to 30μM and 25μM, respectively, have been measured in-vivo [9] . Whilst circulating metal levels are usually highest over the first few months after implantation, persistent elevation occurs as late as 10 years after surgery [10] .
Previous studies have shown that short-term exposure to these metal species may affect human osteoclast and osteoblast survival and function. ) ions is toxic to osteoblasts and reduces cell activity in-vitro [11] [12] [13] . Few data are available on the effect of cobalt and chromium exposure on primary human osteoclasts, although Nichols and Puleo showed short-term exposure to Co and Cr ions at sub-lethal doses resulted in decreased resorptive activity in rat osteoclasts [14] . In contrast, Rousselle et al. found exposure of rabbit osteoclasts to Cr 3+ had no effect on rabbit osteoclast function [15] . Sankaramanivel et al. have shown that rats treated intraperitoneally with potassium dichromate (Cr
6+
) over 5 days led to accumulation of chromium in the femur, and was associated with reduced systemic assays of alkaline phosphatase and tartrate-resistant acid phosphatase, suggesting an impact on both bone formation and resorption [16] . However, the longerterm effect of chronic exposure of both human osteoblasts and osteoclasts to these ions at clinically relevant concentrations, more akin to clinical exposure both systemically and at the level of the hip joint, is unknown.
We hypothesise that chronic exposure of local bone cells to metal ions may contribute to the clinical bone-related complications after MOMHR. The aims of this study were to investigate the effect of both short-term and chronic Co 2+ , Cr
3+
, and Cr 6+ ion exposure at clinically relevant concentrations after MOMHR on human osteoblast and osteoclast proliferation and function, and on mature primary human osteoclasts. A doseranging methodology was used including metal ion levels covering the normal physiological range, through systemic levels found after MOMHR, to the high concentrations reported in hip joint synovial fluid aspirates after MOMHR. , respectively).
MATERIALS AND METHODS

Metal ion preparation and validation of concentrations
Osteoblast Cell Culture
Human SaOS-2 cells (a human osteosarcoma-derived osteoblast cell line) were cultured in T75 flasks containing Dulbecco's modified Eagle's medium (DMEM © Glutamax™, Gibco®
Invitrogen, Paisley, UK) supplemented with 10% FCS, 100 IU/mL of penicillin and 100µg/mL of streptomycin (Sigma, Poole, UK), hereafter termed complete DMEM. The cells were maintained at 37°C in a humidified atmosphere of 95% air and 5% CO 2 until required for assay.
Osteoblast Viability and Proliferation
SaOS-2 cells were seeded at into 96-well plates at 5x10 3 
Osteoblast mineralization
Once 
Human Osteoclast Culture
Osteoclasts were generated from human peripheral blood monocytes taken from healthy volunteers as previously described and with research ethics committee approval [17] .
Sterilisation of 6mm diameter coverslips (Richardson's of Leicester, Leicester, UK) was performed by baking at 180° for 2 hours. Dentine disks (http://www.dentinedisks.com/)
were sonicated and sterilised by washing in 70% ethanol overnight. Venous blood was obtained from healthy volunteers and separated using Histopaque ® -1077 (Sigma). The monocyte fraction was collected, washed and then re-suspended in α -MEM Glutamax (Gibco® Invitrogen, Paisley, UK). An appropriate volume of cell suspension containing 5x10 5 cells was then added to pre-wetted coverslips or dentine disks in a 96 well plate.
Cells were incubated for a minimum of 1 hour to allow adherence to the dentine or glass surface. Non-adherent cells were subsequently washed away with α -MEM. Adherent cells were incubated in 100µl α-MEM Glutamax containing 10% FCS, 100U/mL penicillin, 100µg/mL streptomycin (Sigma) (referred to as complete α -MEM) and supplemented with 25ng/mL M-CSF, 30ng/mL recombinant RANKL (Insight Biotechnology, Wembley, UK) at 37°C in a humidified atmosphere of 93% air and 7% CO 2 for three weeks. To determine the effect of osteoclastogenesis metal ion treatments were added from day 3, whilst for effects on mature osteoclast activity metal ion treatments were added after the onset of resorption (typically 14 days). Complete α -MEM containing 25ng/mL M-CSF, 30ng/mL RANKL and treatments was replaced every 2-3 days.
TRAP staining
Dentine disks were TRAP stained as previously described [18, 19] . Briefly, the disks were fixed in 10% buffered formalin. Disks were then incubated in pre-warmed Acetate-tartrate buffer (0.1M Sodium tartrate (Sigma) in 0.2M Acetate buffer (Sigma), pH5.2) at 37°C for 5 mins, followed by 30 mins incubation at 37°C in 20mg/mL Naphthol AS-BI phosphate (Sigma) /Dimethylformamide (Fisher Scientific, Loughborough, UK) in acetate-tartrate buffer. The disks were then incubated in acetate-tartrate buffer hexazotised pararosaniline solution. The disks were rinsed in water and counterstained in Gill's haematoxylin.
Quantification of Osteoclast Number and Resorption
Resorbing osteoclasts were identified on dentine disks as a TRAP positive cell in or in close proximity to resorption pits and quantified from 8 random fields of view per disk.
Resorption lacunae were identified in the same 8 random fields of view per disk and the plan area of resorption was determined by point counting as previously described [20] . All values were expressed as percentage response relative to vehicle.
Statistical Analysis
All treatment comparisons were made versus vehicle (0µM). Logistic curve fitting was performed using the least squares (ordinary fit) method and a standard Hill slope to calculate IC 50 values where effects on bone cell proliferation were found. Data sets were analysed using ANOVA with Dunnett's multiple comparison post-test or the Kruskal-Wallis test with Dunn's multiple comparison post-test, depending on the normality of the data distribution. All analyses were conducted 2-tailed using a critical p-value of 0.05 using GraphPad Prism® (GraphPad Software, La Jolla, CA).
RESULTS
Effect of short-term exposure to metal ions on osteoblast viability
Treatment up to 2000µM of all ions caused a reduction in the number of viable, metabolically active osteoblasts compared to vehicle after 3 days (Figure 1 
Effect of chronic exposure to metal ions on osteoblast viability and function
Osteoblast proliferation over 13 days was not affected by metal ion concentrations of Co or Cr 3+ up to 5µM (Figure 2A ). However, Cr 6+ at 1 and 5µM reduced osteoblast proliferation over 13-days exposure (p<0.05 and p<0.0001 respectively). These concentrations of Cr 6+ had had no effect on short-term osteoblast proliferation.
ALP , respectively: Figure 2B ). In addition, Cr 6+ exposure also reduced ALP activity to undetectable levels at concentrations of 10µM and 1µM (p<0.05 and p<0.0001, respectively). When ALP activity was corrected for cell number using DNA content, only Cr 6+ reduced ALP activity at the cellular level (10µM =p<0.05 and 100µM =p<0.001). Thus, the suppressed osteoblast activity was largely a function of reduced cell number rather than reduced activity per cell.
Mineralisation activity, measured by Alizarin red staining after 21-days culture in osteogenic medium, was reduced with all metal ion treatments at 100µM (p<0.0001, Figure 2C ). Cr 6+ at 10µM also reduced mineralisation activity (p<0.0001). 
Effect of Co
2+
, Cr
3+
, and Cr 6+ on mature, active osteoclasts
To determine the effects of metal ions on mature, fully functional and active human osteoclasts, human monocytes were isolated, settled onto dentine disks and cultured as above but in the absence of metal ions to allow the fusion cells and formation of osteoclasts. The onset of resorption (an indicator of fully functional and active osteoclasts) was monitored daily from day 10 and once resorption had been detected (typically after 14 days), the osteoclast culture medium was then replaced to include 0.01µM to 200µM Co 
DISCUSSION
In this study we examined the effect of chronic exposure of human osteoblast and primary human osteoclast cells to Co and Cr ions at concentrations including the clinically equivalent range defined by previous reports of measured metal levels in the serum and hip synovial fluid taken from patients after MOMHR. We found that ions of both metals affected osteoblast and osteoclast cell proliferation and function. Our findings are consistent with in-vitro studies using animal cells that supraphysiological concentrations of cobalt and chromium ions induce apoptosis in human osteoblast-like cells in-vitro in a dose-dependent manner [12] , and suppress osteoblast synthetic function [11, 21, 22] . Our dose-ranging data suggest that chronic exposure to Co 2+ or Cr 3+ do not have a major effect on cell viability or synthetic function at concentrations equivalent to those metal levels found in serum or synovial fluid in patients after MOMHR, whilst exposure to Cr 6+ has a profound effect on cell viability at concentrations equivalent to the serum chromium range after MOMHR.
In contrast, our data suggest that an effect of Co and Cr on human primary osteoclasts occurs within the clinically observed concentration range and varies with cell maturity. At systemic levels these ions may have a mild stimulatory effect on developing osteoclasts, but at higher concentrations and in mature osteoclasts their effect is inhibitory.
The reason for this difference might be explained by the substrate resorbing activity of the exposed cell, as mature resorbing osteoclasts may accumulate more intracellular metal ions through phagocytic activity versus developing osteoclasts, and thus demonstrate a greater toxic effect due to greater internalisation of the metal. In support of the increased resorption transient seen in the serum range, Patntirapong et al have shown that cobalt ions in solution or incorporated into calcium phosphate coated plastic at clinically-relevant concentrations increase murine osteoclast differentiation and resorption in-vitro [23] . Whilst cobalt ions do not localise to bone, chromium salts do have an affinity for bone [24] , being trapped in the bone matrix, and thus levels in the bone microenvironment may exceed those found in serum. Albrecht et al have also suggested a possible indirect route for osteoclast activation in response to metal ions, showing that exposure of human peripheral blood mononuclear cells to Co 2+ ions in-vitro results in upregulation of IL-1α, IL-1β, and IL-6 expression, that may in turn increase osteoclast birth rate and resorption [25] .
Differences in the cellular responses to Co 2+ , Cr
3+
, and Cr 6+ are likely complex, with several mechanisms operating. Co 2+ and Cr 6+ ion complexes are highly soluble and readily cross cell membranes via the anion transporter, whilst Cr 3+ complexes are less soluble at physiological pH and cell membrane permeability to Cr 3+ is low [26] . These physicochemical characteristics may explain, in part, the lower toxicity of Cr 3+ relative to the other ions to both osteoblasts and osteoclasts. The high toxicity of Cr 6+ may be explained by its rapid transport across cell membranes and subsequent reduction to Cr 3+ within the cell by glutathione resulting in an increase in oxidative stress leading to cell death. [27] It is currently unclear which chromium species are released from prosthesis surfaces after MOMHR. Metal ion release as a result of corrosion, distinct to that arising from the process of wear, has been identified as a significant contributor to systemic metal release after MOMHR [7, 28] . Merritt and Brown have shown that Cr 6+ is released during the corrosion of orthopaedic implants and is present systemically in-vivo [29] . However, De , and our data show that at clinically relevant levels this would be highly toxic to local osteoblasts and osteoclasts. A recent speciation study of chromium complexes by microfocus x-ray spectroscopy using a synchrotron beam in retrieved tissues around failed MOMHR prostheses showed chromium is present mainly as chromium (III) phosphate. [31] However, as Cr 3+ has poor cell membrane permeability, its presence may arguably be accounted for by its entering the cell as Cr 6+ then being reduced to Cr 3+ , and giving rise to the necrotic lesions for which the biopsies were taken.
Our observation of the toxicity of Co 2+ to osteoclast cells at synovial fluid levels and to osteoblasts at concentrations 3-5 times that found in local tissues after MOMHR may occur through a similar mechanism to that observed in previous studies of lung toxicology.
High concentrations of Co 2+ are thought to induce cell damage by stabilising hypoxia inducible factors (HIF) that bind to DNA and initiate hypoxia-related gene expression and are normally degraded under normal oxygen tensions, resulting in HIF pathway activation and cellular apoptosis [32, 33] .
Our observations that Co and Cr ions at clinically identified levels after MOMHR has several clinical implications for local bone health. Supressed osteoblast activity may explain early aseptic loosening as a failure of primary osseo-integration. In support of this concept, Long et al have reported a 15% failure rate for the Durom acetabular prosthesis in 207 hips within 2 years following implantation [34] . In all cases but 1 aseptic loosening of the prosthesis was the mode of failure, and in 13 prostheses examined in detail at retrieval, all showed failure of osseo-integration of bone onto the fixation surface. Femoral neck narrowing has commonly been reported after MOMHR and may contribute to fracture risk [35] . It has been suggested that narrowing occurs as a result of elevated hydrostatic fluid pressures in these patients, however, and alternative mechanism may be through osteoclast activation at the bone surface due to elevated metal levels. In support of this increased osteoclast numbers have been identified histologically on periosteal surfaces in fracture cases with femoral neck narrowing after MOMHR (Pat Campbell, personal communication). At a systemic bone health level, our data suggest that metal ions release may be sufficient to impact on osteoclast cell activity and number that in turn may affect bone mass and remodelling. The long term implication of systemic metal release after MOMHR for systemic bone health remains to be elucidated.
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